Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular disease posttransplant.

Phuong-Thu T Pham1, Phuong-Chi T Pham, Gabriel M Danovitch

  • 1Division of Nephrology, Kidney and Pancreas Transplantation, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA. ppham@mednet.ucla.edu

Seminars in Nephrology
|July 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety Net kidney after liver transplantation: unexpected renal recovery in a liver transplant recipient after more than 10 months on maintenance hemodialysis - a case report.

Frontiers in nephrology·2026
Same author

Prevalence and Dynamics of HLA donor-specific antibodies in simultaneous liver-kidney transplantation.

Human immunology·2026
Same author

The End Kidney Deaths Act-Reply.

JAMA·2025
Same author

Gabriel M. Danovitch, MD, FRCP (Hon).

Transplantation·2025
Same author

The End Kidney Deaths Act Risks Irreversible Harm to Organ Donation.

JAMA·2025
Same author

The Trojan Horse of Kidney Transplantation Returns: A Review and Call for Financial Neutrality.

Clinical journal of the American Society of Nephrology : CJASN·2024

Kidney transplantation improves survival for end-stage renal disease patients but carries cardiac risks. Managing these cardiovascular complications is crucial for long-term transplant success.

Area of Science:

  • Nephrology
  • Cardiology
  • Transplantation Medicine

Background:

  • Renal transplantation is the primary treatment for end-stage renal disease, enhancing survival and quality of life over dialysis.
  • Despite benefits, post-transplant cardiac complications significantly increase morbidity and mortality in kidney transplant recipients.
  • Cardiovascular mortality is notably higher in transplant recipients compared to the general population, especially in younger age groups.

Purpose of the Study:

  • To review conventional and novel cardiovascular disease risk factors following renal transplantation.
  • To discuss current medical management strategies for these identified cardiovascular risks.
  • To provide an evidence-based overview for clinicians managing kidney transplant patients.

Main Methods:

Related Experiment Videos

  • Comprehensive literature review of studies on cardiovascular complications post-renal transplantation.
  • Analysis of risk factors, including those related to immunosuppressive medications.
  • Synthesis of data on patient outcomes and management approaches.

Main Results:

  • Renal transplantation improves some cardiovascular disease risk factors by restoring kidney function.
  • Immunosuppressive therapies introduce unique cardiovascular risks in transplant recipients.
  • Elevated cardiovascular mortality rates observed in transplant recipients across various age demographics.

Conclusions:

  • Post-renal transplantation requires vigilant monitoring and management of cardiovascular risks.
  • A multifaceted approach addressing both traditional and transplant-specific risk factors is essential.
  • Optimizing cardiovascular health is critical for improving long-term outcomes in kidney transplant recipients.